跳至主要内容
临床试验/NCT02295683
NCT02295683终止不适用

Renal Sympathetic Denervation by Iberis System in Patients With Uncontrolled Hypertension - IBERIS - HTN Registry

Terumo Europe N.V.2 个研究点 分布在 2 个国家目标入组 18 人开始时间: 2014年11月最近更新:
适应症

试验速览

阶段
不适用
状态
终止
发起方
入组人数
18
试验地点
2
主要终点
Blood Pressure (BP) Measurements

研究概览

简要总结

The purpose of this study is to document safety and efficacy of renal sympathetic denervation treatment in subjects with uncontrolled hypertension by using Iberis renal denervation system.

详细描述

This study is a prospective, multi-center, single-arm, non-interventional and open-label registry to collect descriptive data from patients who receive renal sympathetic denervation treatment in accordance with routine hospital practice using Iberis system.

This registry will collect data prospectively from patients that receive renal sympathetic denervation treatment with use of Iberis renal denervation system and treatment will be applied according to the routine hospital practice. No additional tests are required specific to this registry. The registry will serve as a tool to collect clinical data in order to expand the knowledge base of safety, efficacy and functionality of the Iberis system in patients with resistant hypertension.

A minimum of 30 patients will be enrolled in Europe

研究设计

研究类型
Observational
观察模型
Other
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age ≥18 years or minimum age as required by local regulations.
  • Patient has been thoroughly informed about this registry and signed Informed Consent Form.
  • Patient with true resistant hypertension defined as:
  • Office systolic BP higher than 160 or 150mmHg in case of type 2 diabetes
  • Ambulatory BP with average BP>130mmHg or mean daytime>135mmHg in more than 70% of the measurements.
  • Patients should be on stable hypertension therapy for at least 8 weeks before procedure, including spironolactone if they are supposed to be respondent as indicated by the specialized center/excellence unit on hypertension.

排除标准

  • Previous renal artery intervention (balloon angioplasty or stenting).
  • Evidence of renal artery atherosclerosis (defined as a renal artery stenosis >50%).
  • Main renal arteries of less than 4mm diameter or less than 20mm in length.
  • Presence of multiple main renal arteries in either kidney.
  • Estimated glomerular filtration rate <45ml/min per 1,73m2
  • Recent myocardial infarction, unstable angina pectoris or cerebrovascular accident within the past 3-6 months.
  • False resistant hypertension (pseudo resistance) by using 24h ambulatory BP monitoring (ABPM).
  • Secondary arterial hypertension.
  • Pregnancy.
  • There is another pathological process with well-known life expectancy of less than 5 years.
  • Patient unable to do correct FU.
  • Unable to take correct ambulatory BP.
  • Primary hyperaldosteronism.
  • Known lack of adherence to medical treatment.

结局指标

主要结局

Blood Pressure (BP) Measurements

时间窗: Up to 5 year FU

Office BP; Ambulatory BP; Home BP

次要结局

未报告次要终点

研究者

发起方
Terumo Europe N.V.
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验